190A Chordia Therapeutics Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

190A

TSE Growth

Chordia Therapeutics Inc.

150

JPY

-5

(-3.23%)

Apr 30, 11:15 am JST

0.93

USD

Apr 29, 10:15 pm EDT

Result

PTS

outside of trading hours

150

Apr 30, 10:56 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Aug, 2022 ＊	ー	-1,844	-1,776	-1,779	-39.8	0	ー	J-GAAP
Aug, 2023 ＊	2,500	212	225	223	4.0	0	ー	J-GAAP
Aug, 2024	0	-1,801	-1,824	-1,827	-31.1	0	Oct 11, 2024	J-GAAP
Aug, 2025	0	-1,789	-1,769	-1,785	-26.0	0	Oct 14, 2025	J-GAAP
Aug, 2026 Guidance	ー	-2,008	-1,958	-1,960	-26.1	0	Oct 14, 2025	J-GAAP
YoY	－	-12.2%	-10.7%	-9.8%	-0.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Aug, 2024	Jun 14, 2024	ー	-2,273	-2,278	-2,280	0	J-GAAP
- Results	Oct 11, 2024	0	-1,801	-1,824	-1,827	0	J-GAAP
Aug, 2025	Oct 11, 2024	Available in future release
Results	Oct 14, 2025	Available in future release
Aug, 2026	Oct 14, 2025	ー	-2,008	-1,958	-1,960	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Aug, 2019	ー	－	Available in future release
Aug, 2020	ー	－
Aug, 2021	800	－
Aug, 2022	ー	-100.0
Aug, 2023	2,500	－
Aug, 2024	0	-100.0
Aug, 2025	0	－
Aug, 2026 Guidance	ー	－	-2,008	-12.2	-1,958	-10.7	-26.1	-0.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Aug, 2024	0	-1,801	ー	-42.33	-38.30	ー	-31.1
Aug, 2025	0	-1,789	ー	-54.16	-48.82	ー	-26.0
Aug, 2026 Guidance	ー	-2,008	ー	-85.03	-78.03	ー	-26.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,500	212	225	223	4.0
Fiscal Year	Aug, 2023	Aug, 2023	Aug, 2023	Aug, 2023	Aug, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar - Aug, 2024	0	-992	-1,023	-1,025	-17.5	0	Oct 11, 2024	J-GAAP
Mar - Aug, 2025	0	-793	-794	-809	-11.8	0	Oct 14, 2025	J-GAAP
Mar - Aug, 2026 Guidance	ー	-1,346	-1,326	-1,327	-17.6	0	Apr 14, 2026	J-GAAP
YoY	－	-69.7%	-67.0%	-64.0%	-49.5%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Aug, 2023	212	543	543	0	ー	4,799	97.76	J-GAAP
Aug, 2024	-1,801	-1,947	-1,937	-10	1,478	4,329	93.46	J-GAAP
Aug, 2025	-1,789	-1,841	-1,836	-5	61	2,548	95.04	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Sep - Feb, 2023	0	-809	-801	-802	-14.2	ー	ー	J-GAAP
Sep - Feb, 2024	0	-996	-975	-976	-14.3	ー	Apr 11, 2025	J-GAAP
Sep - Feb, 2025	0	-662	-632	-633	-9.0	ー	Apr 14, 2026	J-GAAP
YoY	－	+33.5%	+35.2%	+35.1%	+37.5%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Mar - May, 2024	0	-371	-374	-375	-6.7	-Inf	Jul 16, 2024	J-GAAP
Jun - Aug, 2024	0	-621	-649	-650	-11.1	-Inf	Oct 11, 2024	J-GAAP
Sep - Nov, 2024	0	-624	-615	-616	-9.1	-Inf	Jan 14, 2025	J-GAAP
Dec - Feb, 2024	0	-372	-360	-360	-5.3	-Inf	Apr 11, 2025	J-GAAP
Mar - May, 2025	0	-424	-422	-423	-6.2	-Inf	Jul 14, 2025	J-GAAP
Jun - Aug, 2025	0	-369	-372	-386	-5.6	-Inf	Oct 14, 2025	J-GAAP
Sep - Nov, 2025	0	-306	-294	-295	-4.2	-Inf	Jan 14, 2026	J-GAAP
Dec - Feb, 2025	0	-356	-338	-338	-4.8	-Inf	Apr 14, 2026	J-GAAP
YoY	－	+4.3%	+6.1%	+6.1%	+9.5%

Fiscal Year	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep - Nov, 2023	－	Available in future release
Dec - Feb, 2023	－
Mar - May, 2024	－
Jun - Aug, 2024	－
Sep - Nov, 2024	－
Dec - Feb, 2024	－
Mar - May, 2025	－
Jun - Aug, 2025	－
Sep - Nov, 2025	－
Dec - Feb, 2025	－	-356	+4.3	-338	+6.1	-4.8	+9.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	0	-306	-294	-295	-4.2
Fiscal Year	Nov, 2023	Nov, 2025	Nov, 2025	Nov, 2025	Nov, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Aug, 2023	79.28	91.1	4,909	4,474	-3,894	ー	ー	J-GAAP
Aug, 2024	61.44	89.8	4,632	4,158	-5,721	ー	Oct 11, 2024	J-GAAP
Aug, 2025	35.29	90.8	2,681	2,434	-7,507	ー	Oct 14, 2025	J-GAAP
Sep - Feb, 2025	ー	91.8	2,512	2,305	-633	ー	Apr 14, 2026	J-GAAP

Chordia Therapeutics Inc.(190A) Financial Results